UNITY Biotechnology Inc To Discuss Lead Program UBX1325 Call Transcript
Good morning, and welcome to the Unity Biotechnology Investor Call. (Operator Instructions)
Today's call will be recorded, and a replay will be available on the Unity Biotechnology website.
At this time, I would now like to turn the call over to your host, Lynne Sullivan, CFO of Unity Biotechnology. Please go ahead, Lynne
Good morning. Thank you for joining the Unity Biotechnology Conference Call to discuss the 12-week and 18-week results from our BEHOLD study, a Phase II study of UBX1325 in patients with diabetic macular edema. I'm Lynne Sullivan, Chief Financial Officer of Unity Biotechnology. With me on today's call is renowned retinal specialists, Robert Bhisitkul, Professor of Ophthalmology and Director Retina Fellowship at University of California, San Francisco; Anirvan Ghosh, the CEO of Unity Biotechnology; and Jamie Dananberg, the Chief Medical Officer of Unity Biotechnology.
On today's call, Anirvan will begin with an overview of the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |